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Abstract
Cholangiocarcinoma (CCA) represents the second-most common primary
liver malignancy after HCC and has risen in incidence globally in the past
decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all
CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal
CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested
that iCCA may be a potentially feasible option for highly selected patients.
This has been motivated both by successes noted in outcomes of LT for other
malignancies, such as HCC and pCCA, and by several retrospective reviews
demonstrating favorable results with LT for a selected group of iCCA patients
with small lesions. LT for iCCA is primarily relevant within two clinical scenarios. The first includes patients with very early disease (single tumor, ≤2
cm) with cirrhosis and are not candidates for liver resection (LR). The second
scenario is patients with locally advanced iCCA, but where the extent of LR
would be too extensive to be feasible. Preliminary single-center reports have
described LT in a selected group of patients with locally advanced tumors
who have responded to neoadjuvant therapy and have a period of disease
stability. Currently, there are three prospective trials underway that will help
clarify the role of LT in iCCA. This review seeks to explore the available studies involving LT for iCCA, the challenges of ongoing trials, and opportunities
for the future.

I NTRO DUCTI O N
Cholangiocarcinoma (CCA) is the second-most common primary liver malignancy after HCC.[1] Within the
CCA group, intrahepatic cholangiocarcinoma (iCCA)

arises from intrahepatic bile ducts proximal to the
second-order biliary division.[2] iCCA comprises up to
20% of all CCA, with the rest being extrahepatic, including perihilar CCA (pCCA) and distal CCA.[2] Over
the past decades, the incidence of iCCA has increased

Abbreviations: AJCC, American Joint Committee on Cancer; BED, biological equivalent dose; CA 19-9, carbohydrate antigen 19-9; CCA,
cholangiocarcinoma; EBRT, external beam radiation therapy; iCCA, intrahepatic cholangiocarcinoma; LC, local control; LNM, lymph node metastasis; LR, liver
resection; LRTs, locoregional therapies; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; OPTN, Organ procurement and Transplantation
Network; OS, overall survival; pCCA, perihilar cholangiocarcinoma; RFA, radiofrequency ablation; RFS, recurrence-free survival; SBRT, stereotactic body
radiation therapy; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; TNM, tumor, nodes, and metastases; UNOS, United Network
for Organ Sharing; VI, vascular invasion.
© 2021 American Association for the Study of Liver Diseases.
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globally across all age and ethnicity strata.[3–8]
Paralleling this increase in incidence has been an increase in iCCA-
specific mortality.[9,10] Though iCCA
can arise in both cirrhotic and noncirrhotic livers, risk
factors for its development are similar as for HCC and
include cirrhosis, chronic hepatitis B and C, obesity, diabetes, and alcohol, the latter of which is on the rise
and, along with better disease detection, are a contributing factor to the increased incidence.[11]
The staging of iCCA is based on the tumor, nodes,
and metastases (TNM) staging system from the
American Joint Committee on Cancer (AJCC). The
staging, based on the AJCC 7th edition, was introduced in 2010 and has subsequently been revised as
the AJCC 8th edition.[12–14] Whereas the node (N) and
metastases (M) classification have remained essentially unchanged, except for modifying the lymph node
metastasis (LNM) staging from IVA to IIIB, the tumor
(T) categories classification has undergone significant
reclassification.[14] This included stratifying T1 tumors
into T1a (single lesion up to 5 cm without vascular invasion [VI]) and T1b (single lesion >5 cm without VI). T2
tumors comprise either a single lesion of any size with
VI, or multiple lesions of any size or number, with or
without VI. T3 tumors perforate the visceral peritoneum,
and T4 tumors involve local extrahepatic structures by
TA B L E 1

direct invasion.[14] A detailed outline of the staging of
iCCA tumors according to the AJCC 7th and 8th editions is shown in Table 1.
According to the National Comprehensive Cancer
Network guidelines, iCCA patients with resectable disease should undergo liver resection (LR) together with
regional lymphadenectomy (RLA).[15] For patients with
unresectable or metastatic disease, options include
clinical trials, systemic therapy, external beam radiation
therapy (EBRT) with concurrent fluoropyrimidine, locoregional therapy (LRT; such as arterially direct therapies), and best supportive care.[15]
Unfortunately, many patients have advanced or disseminated disease at diagnosis, which limits treatment
options.[3,16] As a result, the 5-year overall survival (OS)
for all comers is <10%.[17] LR represents the mainstay
treatment option with curative potential for patients who
meet criteria for resection (absence of diffuse bilobar
involvement and satellite lesions, peritoneal carcinomatosis, distant metastases, underlying liver disease
precluding safe resection, an estimated future liver
remnant <20%–
30% with inadequate response to
portal vein occlusion, or severe comorbidities).[18] For
patients who can undergo LR, >70% require a major
hepatectomy (three or more segments) to achieve a
microscopic negative margin resection (R0).[16,19,20] In

iCCA AJCC staging 7th and 8th editions
AJCC 7th Edition

T category
T1

AJCC 8th Edition
T category

Solitary tumor without VI

T1a

Solitary tumor ≤5 cm without VI

T1b

Solitary tumor >5 cm without VI

T2

Solitary tumor with intrahepatic
vascular tumors, with or without
VI

T2a

Solitary tumor with VI

T2b

Multiple tumors, with or without VI

T3

Tumor perforating the visceral peritoneum or involving
local hepatic structures by direct invasion

T3

Tumor perforating the visceral
peritoneum

T4

Tumor with periductal invasion

T4

Tumor involving local extrahepatic
structures

N0

No regional LNM

N0

No regional LNM

N1

Regional LNM present

N1

Regional LNM present

M0

No metastasis

M0

No metastasis

M1

Metastasis present

M1

Metastasis present

N category

M category

TNM stage

TNM stage

I

T1 N0 M0

II

T2 N0 M0

III

T3 N0 M0

IVA

T4 N0 M0/any T N1 M0

IVB

Any T1 any N M1

IA

T1a N0 M0

IB

T1b N0 M0

II

T2 N0 M0

IIIA

T3 N0 M0

IIIB

T4 and/or N1 M0

IV

Any T any N M1
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addition to performing a margin negative resection, an
RLA is recommended by the International Liver Cancer
Association guidelines, which includes at least six
nodes, to aid in prognostication.[2]
Given the poor outcomes, high recurrence rates,
and the limited curative treatment options for patients
with iCCA, LT has re-emerged as a therapeutic strategy. This has been fueled, in part, by the success of LT
in the management of other hepatic malignancies that
were previously contraindicated for LT. Within this context, there have been excellent oncological outcomes
with LT for patients with HCC, even if standard criteria
like the Milan criteria are exceeded. Success has also
been demonstrated for selected patients with localized
pCCA treated with neoadjuvant chemoradiotherapy followed by LT. In the past decade, there has been an accumulation of data on oncological outcomes of patients
who have undergone LT for early iCCA, predominantly
as an incidental diagnosis or for a presumed HCC.[21]
More recently, efforts have been taken to push the envelope further and evaluate the outcomes for a select
group of patients with locally advanced disease who
have received neoadjuvant therapy for downstaging.[22]
As a result of these efforts, several clinical trials are
ongoing to further clarify the outcomes of patients with
iCCA undergoing liver transplantation (LT) in a prospective fashion. Consequently, the current status of
LT for iCCA warrants appraisal and whether it is ready
to be considered a formal indication for LT.
This review will evaluate evidence related to the
above-mentioned clinical scenarios.

OUTCO M ES A N D CH A LLENG ES
W ITH LI V ER R ESECTI O NS
FO R i CCA
LR is the standard of care and is currently the only curative treatment option in patients with iCCA. This typically
consists of a segmental resection plus portal lymphad
enectomy.[23–25] When possible, minimally invasive surgery may have a role in enhancing recovery and potentially reducing complications, though this is not always
feasible, and comparative data between open and minimally invasive surgery in this setting are lacking.[26–28]
Unfortunately, despite achieving a margin-negative resection, long-term oncological outcomes are poor, with
5-year survivals between 30% and 40% and low cure
rates (9.7%; 95% CI, 6.1–13.4).[29–31] Recurrence rates
after LR are high, with the initial recurrence being intrahepatic in 60%–70%.[19,32] Though patients with very
early iCCA (≤2 cm; with no LNM or VI) can achieve excellent outcomes (100% at 5 years) based on a nation-
wide survey of the Liver Cancer Study Group of Japan,
slightly larger tumors, defined as ≤5 cm, even in the
absence of aggressive pathological features, such as
VI, poor grade, LNMs, and periductal histology, only
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have a cure fraction of 25.8%.[29,33] Moreover, though
LR represents the mainstay of therapy, most patients
will not be candidates because of factors such as unfavorable tumor location, cirrhosis/portal hypertension,
multifocal disease, or extrahepatic disease.[18] Based
on a high-volume, single-institution experience of 564
patients, 66% of consecutive iCCA patients underwent
resection.[34] On a population scale, however, only 15%
of patients with iCCA underwent resection based on
an analysis of the Surveillance, Epidemiology, and End
Results (SEER) Program between 1983 and 2010.[35]
These factors highlight that significant progress is
needed to improve patient outcomes. Within this context, it is imperative to note that retrospective studies
that perform comparative evaluations between LR and
LT are likely to be subject to selection bias and both
unmeasured and residual confounding, given the highly
distinct patient populations across the two treatment
modalities.

LT FO R i CCA
The role of LT in iCCA is relevant within two clinical scenarios. The first scenario includes very early iCCA in
patients who are not amenable to LR, typically because
of significant underlying liver dysfunction. The second
scenario includes patients with more locally advanced
iCCA, but where the extent of LR required would be
unfeasible. The option for this latter group of patients
typically includes neoadjuvant therapy tumor control
and selection.
iCCA has long represented a formal contraindication for LT globally because of historically dismal outcomes.[36– 40] Many available studies are based on
single-center analyses with few patients with limited
statistical power. Some studies analyze patients with
both iCCA and pCCA, and patients with and without
liver cirrhosis have been included in the analyses.[41,42]
This heterogeneity in some of the analyzed patient
populations has limited the inferences that can be
made. There has, however, been a recent reappraisal
of the role of LT with both single-and multi-institutional
studies demonstrating favorable results in patients who
underwent LT for other indications.[21,43] Given the contraindication of iCCA for LT, many of these patients were
either diagnosed incidentally on explant pathology or
were incorrectly diagnosed as having HCC before LT.

LT FO R SM A LL UNR ESECTA BLE
i CCA
Sapisochin et al., in 2014, performed a retrospective,
multicenter study on 16 Spanish transplant centers,
which identified 29 patients with cirrhosis with iCCA in
the liver explant, many of whom had a pre-LT diagnosis
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of HCC.[21] Of these patients, 8 had “very early” iCCA
(≤2 cm), and 4 of these 8 were incidental tumors. Tumor
recurrence risk was associated with larger tumor size
and volume, microscopic VI, and poor tumor differentiation. Compared to patients with single tumors >2 cm,
the very early iCCA group had no tumor recurrence
versus 36.4% in the larger-tumor-size group with a median follow-up of 36.4 months (median follow-up of 51.9
months in the very early iCCA group). The actuarial
survival for the very early iCCA group was excellent
with 1-, 3-, and 5-year survival rates of 100%, 73%, and
73 versus 71%, 43%, and 34% in the larger-tumor-size
group (p = 0.2).[21] This study was followed by a larger,
retrospective, international multi-
institutional series
in 2016, including 17 major transplant centers.[43] The
study cohort comprised patients who had undergone
LT for HCC or decompensated cirrhosis and had iCCA
incidentally identified at explant. In the study period
2000–2013, 48 patients had iCCA only. Of these, 15
(31%) were “very early” and 33 (69%) were larger (>2
cm) or multifocal iCCA. The 1-, 3-, and 5-year cumulative incidence of recurrence was 7%, 18%, and 18% for
the very early iCCA group versus 30%, 47%, and 61%
for the advanced group (p = 0.01). The corresponding
1-, 3-, and 5-year survival rates were 93%, 84%, and
65% in the very early iCCA group versus 79%, 50%,
and 45% in the advanced group (p = 0.02).[43] It is
noteworthy that the 5-year recurrence rate of 18% and
5-year survival of 65% are within the accepted standard oncological outcomes expected of HCC, a well-
established indication for LT.
There have been several additional studies for LT
in the setting of small iCCA, which have demonstrated
overall mixed results regarding survival and recurrence
rates (Table 2). There is significant heterogeneity in the
study populations, with varying tumor sizes, inclusions
(including patients with concomitant HCC nodules), and
grouping iCCA with mixed HCC-CCA. The rationale for
the latter grouping is that distinguishing between iCCA
versus mixed HCC-
CCA for a definitive presurgical
diagnosis is challenging and may not be feasible and
thus more consistent with real-life clinical practice.[44] It
is worth noting that these mixed-type, or biphenotypic,
tumors typically have a prognosis between pure HCC
and pure CCA.[45] A recent meta-analysis from 2020
was based on 18 studies comprising 355 patients together with a registry-based study of 385 patients. The
pooled 1-, 3-, and 5-year OS rates were 75% (95% CI,
64–84), 56% (95% CI, 46–67), and 42% (95% CI, 29–
55), and corresponding recurrence-free survival (RFS)
rates of 70% (95% CI, 63–75), 49% (95% CI, 41–57),
and 38% (95% CI, 27–50).[46] Cirrhosis was positively
associated with RFS (the higher the proportion of patients with cirrhosis, the higher the RFS), whereas an
incidental diagnosis was not associated with RFS.[46]
Moreover, neither cirrhosis nor an incidental diagnosis
was associated with OS.[46] The researchers found a

pooled overall recurrence rate of 43% (95% CI, 33–
53) over a mean follow-up of 40.6 ± 37.7 months.[46]
On a subgroup analysis of only patients with very early
(single iCCA, ≤2 cm) disease, the pooled 5-year RFS
(67%; 95% CI, 47–86) was better than in patients with
more locally advanced iCCA (34%; 95% CI, 23–46).[46]

LR V ERSUS LT
The favorable outcomes noted in some studies for LT
in iCCA have led to some groups seeking to compare
how these outcomes may compare to those of LR.
Hue et al. evaluated the U.S. hospital-based National
Cancer Database, which captures >70% of all newly
diagnosed cancer cases in the USA,[47] in a contemporary era with modern chemotherapy (2010–2016), for
a comparative evaluation of outcomes between iCCA
patients who underwent LR and LT.[48] The researchers performed a propensity-
score–
matched analysis
matching the two treatment groups (1879 LR and 74
LT) based on age, sex, race, ethnicity, insurance payor,
income, education, Charlson-Deyo comorbidity score,
facility type, clinical T stage, receipt of neoadjuvant single-or multiagent chemotherapy, and receipt of radiotherapy.[48] After 1:1 matching, there were 57 patients
in each group. The groups were similar in postoperative outcomes and survival (1-, 3-, and 5-year survival
86.9%, 55.4%, and 38.8% for LT vs. 82.4%, 47.0%, and
34.9% for LR).[48] A subgroup analysis of patients with
pathological T0-T2 disease (solitary tumor with intrahepatic VI or multiple tumors, with or without VI, regardless of size—presumably based on the AJCC [7th and
8th editions]) similarly demonstrated no differences in
survival between the groups.[48] The researchers concluded that given similar outcomes between the groups,
LR should remain the preferred treatment option for
patients with localized iCCA. It should be emphasized
that this represents results from a database analysis,
and patients selected for LT were likely to have advanced underlying cirrhosis. The researchers also recognized, though, that there were limitations with the
analysis, including the unavailability of a fibrosis/cirrhosis score, Model for End-Stage Liver Disease (MELD)
score, functional status, detailed information on (neo)
adjuvant therapy (such as the number of cycles completed), information about predicted future liver remnant, the number of tumors within the liver, and detailed
operative information, such as blood loss, whether a
tumor had been deemed to be surgically resectable,
or information on any previous hypertrophic liver management such as portal vein embolization or associating liver partition and portal vein ligation for staged
hepatectomy.[48] Moreover, the high rate of neoadjuvant
chemotherapy (61.4% of LT patients) and neoadjuvant
radiation (42.1% of LT patients) has raised some skepticism, especially given that iCCA does not represent an

1988 —

1990 —

O’Grady et al.[35]

Yokoyama
et al.[76]

Shimoda et al.

[78]

Casavilla et al.

[36]

25

2

13

Total

16

5

—

7

—

—

—

—

—

20
—

18

—

8

8 (40)

—

—

62

70

60

50

39

29

21.4

0

38.4 10

39

18

17.1

—

—

Pre-LT
Patient Survival
Known
Years (%)
Incidental, Misdiagnosed iCCA, n Cirrhosis,
n (%)
as HCC, n (%) (%)
n (%)
1
3
5

70

67a

—

—

—

1

35

31a

—

—

—

3

35

31a

—

—

—

5

Recurrence- Free
Survival Years (%)

—

—

—

—

—

1

—

—

—

—

—

5

(Continues)

—

—

—

—

—

3

Recurrence Rate
Years (%)

   

IVb (any tumor number, size and
regional LNMs and metastatic
disease), 2 pts

IVa (mutiple tumors in more than one
lobe or tumor invasion of major portal
or hepatic venous branch with or
without regional LNMs), 7 pts

III (tumor[s] of any size with or without
VI with regional LNM), 3 pts

II (single ≤2 cm with VI or multiple
tumors in one lobe all ≤2 cm no
VI; or solitary tumor >2 cm without
VI), 2 pts

I (single ≤2 cm, no VI), 2 pts

2001 pTNM stage

Distant metastasis, 3 pts

T4: multiple, more than one lobe.
Invasion of major branch of portal
or hepatic veins, 10 pts

T2: solitary, ≤2 cm, with VI. Multiple,
one lobe, ≤2 cm, without VI.
Solitary, >2 cm, without VI with
regional nodes or T3 solitary, >2
cm, with VI. Multiple, one lobe, >2
cm, with or without VI, 4 pts

1997 T1, solitary, ≤2 cm, without VI ±
20
regional nodes or T2: solitary,≤2
cm, with VI. Multiple, one lobe, ≤2
cm, without VI. Solitary, >2 cm,
without VI, 3 pts

N1, hepatoduodenal ligament, 8 pts

T3: adjacent structures, 13 pts

T2: perimuscular connective tissue,
10 pts

T1: ductal wall, 2 pts

Pichlmayr et al.[77] 1996 (Sizes not detailed)

Year Tumor Size

LT for iCCA

Author

TA B L E 2
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2011 ≥5 cm, 16 pts

2011 TNM version unclear

Hong et al.[37]

Fu et al.

Facciuto et al.

2014 Overall, 29 pts

Sapisochin
et al.[17]

Goodman type II: mixed HCC-CCA in
same nodule or mixed HCC-CCA
+ concomitant HCC nodules, 12
pts

Goodman type I: iCCA and HCC
separate nodules, 9 pts

iCCA, 7 pts

2015 Combined iCCA/mixed HCC-CCA for 7
analyses

4

29 (100)

—

10 (100)

—

6 (55)

—

4 (20)

3 (30)

4 (17)

50

65

—

79

78

80

68c

71

57

43

73

61

22

60

42c

50.5 50.5

—

84.2 32.7

70

77

71

—

—

—

—

8

25

—

7

13

100

—

—

4 (40)

—

3

—

—

3

10

Multiple or single >2 cm, 21 pts

23 (79)

6 (100)

6 (60)

16 (49)

—

—

20 (100)

—

10 (44)

≤2 cm, 8 pts

29

2014 Tumor size ranged from 2 to 6 cm; 5 6
of 6 pts had solitary lesions, and 2
of 6 pts had poorly differentiated
tumors.

>2 cm and multiple, 1 pt

Single >2 cm, 5 pts

10

33

Patkowski
et al.[83]

[84]

2013 Single ≤2 cm, 3 pts

Vallin et al.[82]

≤2 cm and multiple, 1 pt

2011 Not detailed

Friman et al.[81]

11

25

20

10

23

Total

57

43

73

45

—

24

33c

—

—

21.8

33

42

Pre-LT
Patient Survival
Known
Years (%)
Incidental, Misdiagnosed iCCA, n Cirrhosis,
n (%)
as HCC, n (%) (%)
n (%)
1
3
5

—

45

3

—

27

5

42

32

—

74

0

89

60

40

—

—

58

0

71

0

50

—

44

58

0

71

—

50

—

51.9 51.9 —

69

55.6 28.8 18.8

—

68

1

Recurrence- Free
Survival Years (%)

—

—

—

—

—

—

—

—

—

—

1

—

—

—

—

—

—

—

—

—

—

3

—

—

—

—

—

—

—

—

—

—

5

Recurrence Rate
Years (%)
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IIIC: 3 pts

IIIA: 3 pts

II: 2 pts

I: 3 pts

2011 >5 cm, 16 pts

Hu et al.[80]

T4N1M0,b 2 pts

T4N0M0,b 4 pts

T3N0M0,b 4 pts

T2N0M0,b 9 pts

2004 T1N0M0, 4 pts

b

Year Tumor Size

2008 —

[61]

(Continued)

Sotiropoulos
et al.[79]

Robles et al.

Author
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Multiple or single >2 cm, 28 pts (on
pathology)

2018 Single ≤2 cm, 16 pts (on pathology)

Single >2 cm, 10 pts

≤2 cm and multiple, 2 pts

2017 Single ≤2 cm, 4 pts

44

16

Krasnodebski
et al.[87]

Multiple or single >2 cm, 7 pts

2020 Single ≤2 cm, 1 pt

Single and >2 cm, 1 pt

Multiple and >2 cm, 5 pts
8

Lunsford et al.[18] 2018 Locally advanced disease status after 6
neoadjuvant therapy

Lee et al.[40]

Jung et al.[86]

Tumor differentiation well/moderate/
poor 0/3/1

Pathology largest lesion (cm), 2.7 ±
0.4

Pathology lesion number, 1.0 ± 0.0

Elshamy et al.[64] 2017 Combined iCCA/mixed HCC-CCA for 4
analyses

15

2016 Single ≤2 cm, 15 pts

Sapisochin
et al[39] (very
early)

5

Total
33

2015 —

Year Tumor Size

2016 Single >2 cm or multiple tumors, 33
pts

[85]

(Continued)

Sapisochin
et al.[39]
(advanced)

Lindner et al.

Author

TA B L E 2

4 (50)

—

3 (18)

1 (6)

2 (50)

7 (47)

8 (24)

2 (40)

4 (50)

—

—

14 (88)

2 (50)

—

—

—

—

6 (100)

—

—

4

—

—

—

8 (100)

1 (17)

—

12 (13)

—

15 (100)

33 (100)

—

d

60

52.4

51k

84

50

62.5

e

d

—

37.5

e

54.5

—

52.4

51k

65

45

75

100

37.5

83.3

63.6 63.6

g

g

25

83.3

63.6

g

77.0f 69.0f 62.5f

87.5

e

78.6 —

62.5 62.5

81.3

85k

93

79

—

Pre-LT
Patient Survival
Known
Years (%)
Incidental, Misdiagnosed iCCA, n Cirrhosis,
n (%)
as HCC, n (%) (%)
n (%)
1
3
5

50

—

—

51k

—

—

—

3

50

—

—

41k

—

—

—

5

71.4 28.6 28.6

50

—

—

68k

—

—

—

1

Recurrence- Free
Survival Years (%)

50.0

d

56.2

18

47

—

3

58.0

f

58.0f

47.5e

—

78.1

18

61

—

5

—

—

—

—

(Continues)

—

—

29.0g 42.0g 42.0g

30.0

f

21.0e 47.5e

50.0

d

56.2

7

30

—

1

Recurrence Rate
Years (%)
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44

49 (100)

87
65j

88h
i

87j

92

65h
i

76

90

65j

69

i

65h

67

80j

78

i

81h

87

1

75j

69

i

74h

79

3

75j

55i

74h

75

5

Recurrence- Free
Survival Years (%)

—

1

—

3

—

5

Recurrence Rate
Years (%)
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Abbreviations: cHCC, combined hepatocellular-cholangiocarcinoma; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; LT, liver transplant; pts, patients; pTNM, pathological TNM.
a
Tumor-free survival.
b
TNM 5th edition, Sobin et al., Union for International Cancer Control.
c
Based on patients undergoing LT after 1995 (n = 19).
d
Patients with iCC alone (n = 8).
e
Patients with single ≤2 cm based on pathology (n = 16).
f
Patients multiple or single >2 cm based on pathology (n = 28).
g
Patients with single ≤2 cm (n = 12) based on pre-LT imaging.
h
iCCA and cHCC-CCA combined tumor size >2 but ≤5 cm (n = 24).
i
≤2 cm iCCA and mixed HCC-CCA combined tumors (n = 25).
j
>2 and ≤5 cm iCCA and cHCC-CCA combined tumors (n = 24).
k
iCCA and mixed HCC-CCA combined tumors (n = 13).
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accepted LT indication in the USA and hence receiving such treatments would be unlikely, given that most
would presumably only be identified incidentally on the
liver explant.[49] Though smaller case series have evaluated outcomes of LT in iCCA patients who received
previous neoadjuvant therapy, these numbers are significantly lower than those presented.[22,48,50] This may
be related to issues inherent to large registries, such as
misclassification. Some pCCA or HCC may have been
classified as iCCA, which would explain the discrepancies in neoadjuvant therapy use, given that pre-LT therapies are common in these entities in the Mayo Clinic
protocol (which has been used as a basis for approving
pCCA as an indication for LT as approved by the Organ
Procurement and Transplantation Network [OPTN]
and the United Network for Organ Sharing [UNOS])[51]
and as bridging therapy in patients with HCC.[52,53]
Notwithstanding these limitations, this demonstrates
at least equipoise between the treatment modalities.
Finally, it is important to mention that LR and LT in this
setting are complementary given that LT is offered to
patients with nonresectable disease.
Recently, De Martin et al. performed a multicenter
study, including three French Tertiary Hepatobiliary
centers, comparing outcomes of patients with cirrhosis
who underwent LT or LR between 2002 and 2015 with
iCCA or mixed HCC-
CCA found incidentally.[54] The
researchers included iCCA and mixed HCC-
CCA in
their analyses, with all tumors being ≤5 cm. There were
49 patients in the LT group and 26 in the LR group.[54]
Overall, LT had a higher 5-year RFS (75% vs. 36%;
p = 0.004). Similarly, for the subgroup of tumors >2 and
≤5 cm, LT had a nonstatistically significantly higher 5-
year RFS (74% vs. 40%; p = 0.06) and a nonstatistically significantly lower recurrence rate (21% vs. 48%;
p = 0.06).[54] Based on forward step-wise regression
modeling, the researchers found that LT was associated with a lower risk of recurrence (HR, 0.23; 95% CI,
0.07–0.82; p = 0.02), with factors being associated with
a higher risk being the size of the largest nodule and
tumor differentiation.[54] The 5-year OS rate for patients
who underwent LT and had tumors ≤2 cm and >2 to ≤5
cm was 69% and 65%, with no differences in survival
noted between the LT patients who had pure iCCA and
those with mixed HCC-CCA (p = 0.29).[54] The effect of
preoperative treatments, the proportion of which was
higher in the LT group (TACE, 55% vs. 4%; p = 0.005),
the response to such therapies, and the impact and
response of biomarkers such as carbohydrate antigen
19-9 (CA 19-9) is not clear.[54] Moreover, the analysis
was by design per protocol, evaluating the outcomes
from the time of LT rather than the time of listing. As
such, it remains unclear what proportion of iCCA and/
or mixed HCC-CCA patients may experience waitlist
dropout attributable to tumor progression.
Despite several recent studies that have evaluated
comparative outcomes between LR and LT for iCCA, as
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mentioned previously, it is unlikely that a fair comparison between the groups is possible given the selection
bias that is likely inherent in the retrospective design.
Moreover, a randomized controlled study between the
two modalities is challenging. Given that iCCA does
not represent a formally accepted indication for LT, the
patients were either preoperatively determined (erroneously) to have HCC or had iCCAs discovered incidentally on explant pathology. Given the prevailing organ
scarcity, a patient with an iCCA amenable to LR should
undergo LR.[2] However, the clinical scenario involving
a patient with localized disease, who has a contraindication to undergoing LR, is more challenging and remains to be fully elucidated. The options, in this case,
include a potential LT, currently only in a clinical trial
setting, LRTs, or palliative systemic therapy.

OUTCO M ES W ITH LRTs FO R
PATI ENTS W ITH LI V ER- O NLY i CCA
NOT A M EN A BLE TO LR
There are several LRT options for patients that have
disease localized to the liver. Given that LT represents
a potential alternative for these patients, a discussion
of oncological outcomes with nonsurgical therapies is
warranted.

Ablation
There are limited data on the use of ablation for iCCA
compared to HCC. For nonsurgical patients with small
lesions, ablation may represent a valuable option,
though the main limitation is a high recurrence rate.[55]
Using data from the SEER database, Xiang et al. evaluated patients with small ≤5-cm iCCA and compared
OS and cancer-
specific survival (CSS) between LR
(n = 150) and radiofrequency ablation (RFA; n = 34).[55]
The 1-, 3-, and 5-year OS were 87.4%, 73.3%, and
61.5% for LR versus 89.9%, 42.4%, and 23.9% for RFA
(p < 0.001), and corresponding CSS rates of 91.5%,
73.8%, and 66.1% for LR versus 93.5%, 53.4%, and
30.0% (p < 0.001).[55] The difference was greater between the groups in the single iCCA <5-
cm group
(p = 0.001, favoring LR) compared with the single-
iCCA <3-cm group (p = 0.27).[55] Diaz-Gonzalez et al.
recently evaluated ablation outcomes for iCCA based
on data from a single center.[56] Differences in survival
were noted with a greater median OS of patients with
a single lesion ≤2 cm (94.5 months) versus a single lesion >2 cm (24.3 months; p = 0.04).[56] There was a
nonstatistically significantly shorter time to recurrence
in patients with a single lesion >2 cm than those with a
single lesion ≤2 cm (p = 0.1).[56] Brandi et al., from Italy,
similarly found that a tumor size ≥2 cm is associated
with lower local tumor progression-free survival and
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may represent a cutoff for the use of RFA in this setting.[57] In a systematic review and meta-analysis from
2015, including seven observational studies comprising
84 patients, the pooled 1-, 3-, and 5-year survival rates
were 82%, 47%, and 24% for RFA in patients with unresectable iCCA.[58]

Transarterial chemoembolization,
Radioembolization, Hepatic artery
infusion of chemotherapy, and
Transarterial Radioembolization
A meta-
analysis of transarterial chemoembolization
(TACE) in patients with unresectable iCCA, including
16 articles (n = 542), found that median survival times
from the time of diagnosis and first treatment was
15.7 ± 5.8 and 13.4 ± 6.7 months, respectively.[59] The
weighted 1-year survival rate was 58.0% ± 14.5%.[59] A
recently published systematic review and pooled analysis of LRTs in iCCA found a pooled mean weighted
OS of 18.9 months (95% CI, 14.2–
23.5) for EBRT,
14.1 months (95% CI, 12.1–
16.0) for radioembolization, 15.9 months (95% CI, 12.9–19.0) for TACE, and
21.3 months (95% CI, 15.4–
27.1) for hepatic artery
infusion.[60] Another recent systematic review and
meta-analysis by Mosconi et al. specifically evaluated
intra-arterial therapies such as TACE and transarterial
radioembolization (TARE).[61] Thirty-one articles comprising 1695 patients (TACE, n = 906; TARE, n = 789)
were identified.[61] Median survival was similar between
TACE (14.2 months; 95% CI, 11.6–
17.6) and TARE
(13.5 months; 95% CI, 11.4–16.1).[61] Unfortunately, the
significant heterogeneity in the available literature precludes the development of firm recommendations for
selecting one LRT over another.

Proton beam therapy
Proton beam therapy represents a newer possible treatment option for patients with iCCA. A multi-institutional
phase II study from the USA evaluated high-dose hypofractionated proton beam therapy in patients with
localized, unresectable HCC and iCCA.[62] In the 37
patients with iCCA, the local control rate (as defined by
the Response Evaluation Criteria in Solid Tumors 1.0
criteria) at 2 years was 94.1% with an OS rate at 2 years
of 46.5%.[62] Favorable results have been replicated
in subsequent studies. Parzen et al. evaluated a prospective U.S. Proton Collaborative Group registry (nine
institutions between 2013 and 2019), with 25 unresectable and treatment-naïve iCCA patients demonstrating
a local control rate at 1 year of 90.9% and a 1-year
OS rate at 81.8%.[63] A study from Japan evaluated outcomes in 37 unresectable iCCA patients and found 1-
and 2-year OS rates of 60.3% and 41.4%, with 1-and

2-year local control (LC) rates of 100% and 71.5%, respectively.[64] Though short-term tumor control appears
favorable with proton beam therapy, the durability of
oncological outcomes remains to be clarified.

EBRT and stereotactic body
radiation therapy
There is a role of EBRT and stereotactic body radiation
therapy (SBRT) for patients with unresectable iCCA.[15]
Within this, a combination of chemotherapy and radiotherapy may be beneficial, particularly for purposes
of downstaging.[65,66] Tse et al. from the University of
Toronto described the outcomes of SBRT for 10 patients with unresectable iCCA and Child-Pugh A cirrhosis not suitable for standard therapies from 2003 to
2006.[67] In this study, a median survival of 15.0 months
(95% CI, 6.5–29.0) and a 1-year overall survival rate
of 58% (95% CI, 23–83) were reported.[67] Thereafter,
Chen et al. performed a larger, albeit retrospective,
evaluation of 84 patients with unresectable iCCA
from 1998 to 2008.[68] Of these, 35 received EBRT
(five times weekly with a median dose of 50 Gy), and
the remaining 49 patients comprised the non-
EBRT
group.[68] The researchers noted a complete response
and partial response rate of the primary tumor in 9%
and 29% of patients, with corresponding proportions
in the LNMs of 20% and 40%.[68] Median survival of
the EBRT group was 9.5 versus 5.1 months in the non-
EBRT group.[68] More recently, Tao et al., from the MD
Anderson Cancer Center, evaluated a retrospective
cohort of 79 consecutive unresectable iCCA patients
who received definitive radiation therapy from 2002 to
2014.[69] Median tumor size was 7.9 cm, and the majority (n = 70; 89%) of patients had received systemic
chemotherapy before the radiation therapy. Median OS
from the time of diagnosis was 30 months with a 3-
year OS of 44%.[69] The researchers noted that higher
radiation doses correlated with an improved LC and
OS rate. When stratified by the biological equivalent
dose (BED) of 80.5 Gy (deemed to represent an ablative dose), the 3-year OS was 73% in the higher-dose
group (>80.5 Gy) versus 38% for the lower-dose group
(≤80 Gy; p = 0.02).[69] Similarly, the LC rate was statistically significantly higher for the higher-BED group
(78%, >80.5 Gy vs. 45%, ≤80.5 Gy; p = 0.04).[69] The
BED delivered was associated with a favorable LC and
OS hazard on multivariable analysis.[69] More recently,
in 2019, Frakulli et al. performed a systematic review of
the role of SBRT in advanced CCA.[70] The researchers included 10 studies (231 patients), with a primary
outcome being OS and secondary outcomes being LC
and toxicity rates.[70] The pooled 1-year OS was 58.3%
(95% CI, 50.2–66.1) and 2-year pooled OS 35.5% (95%
CI, 22.1–50.1).[70] The pooled 1-
year LC was 83.4%
(95% CI, 76.5–89.4), with the reported toxicities being
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deemed to be acceptable and manageable. The researchers concluded that SBRT may yield outcomes
equivalent to standard chemotherapy and radiotherapy
options and could be considered a therapeutic option
for patients with advanced CCA.[70] It should be noted,
however, that the studies included in this systematic review were heterogeneous, and both primary intra-and
extrahepatic CCA were included, as well as recurrent
or metastatic disease.[70]

Immunotherapy
The role of immunotherapy, particularly checkpoint
inhibition in patients with advanced CCA, continues
to emerge and represents an exciting potential future
therapeutic option in patients with iCCA. Recently, the
TOPAZ-1 phase III clinical trial (randomized, double-
blind, placebo-controlled, multicenter, global trial) demonstrated durvalumab (an immune checkpoint inhibitor
and human monoclonal antibody that blocks the interaction of programmed death ligand 1 on tumor cells
with programmed cell death 1 and CD-80 on T cells)
in combination with standard-
of-
care chemotherapy
(gemcitabine plus cisplatin) to have a statistically significant OS benefit versus chemotherapy alone as the
first-line therapy in patients with advanced biliary tract
cancer (iCCA, extrahepatic CCA, and gallbladder cancers).[71] The study is still ongoing, and the estimated
study completion date is the middle of 2022.[72]

LOCA LLY A DVA NCE D
UNR ESECTA BLE i CCA A N D
NEOA D JU VA NT TH E R A PY
LT for large, locally advanced, unresectable iCCA is
generally contraindicated, given the high recurrence
rate and low OS rates.[1-3] The largest series was a multicenter report from Spain, which included 23 patients
with iCCA and noted a 5-year survival of 42%, with superior survival noted in those with smaller tumors and
those without perineural invasion.[73]
However, whether the addition of neoadjuvant therapy can result in acceptable outcomes is an area of
renewed interest following the publication of a prospective series of 6 patients transplanted following neoadjuvant therapy by Lunsford et al., in 2018.[22] In this
series, the neoadjuvant therapy involved a heterogenous strategy consisting of gemcitabine and cisplatin
for all patients. Three patients also received erlotinib;
1 received FOLFIRI (folinic acid, fluorouracil, and
irinotecan), and 1 received fluorouracil (n = 1). There
was a mandatory minimum period of 6 months showing sustained response after the chemotherapy. The
protocol included repeat imaging (including contrast-
enhanced CT or MRI of the abdomen and pelvis, CT
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of the chest, and bone scans) every 3 months, which
should demonstrate stable or regressing disease and
absence of extrahepatic disease. Two patients underwent resection before LT, and 1 was treated with radiation consisting of 40 Gy in five fractions to a surgical
margin that was microscopically positive after initial
resection. Median time to transplant from the time of
diagnosis was 22 months. Following LT, all patients
received adjuvant therapy consisting of gemcitabine
(n = 4), capecitabine (n = 1), and gemcitabine plus
capecitabine (n = 1). Recurrence occurred in 3 of 6
patients at a median of 7.6 months, whereas the remaining 3 patients have had no recurrence. One patient died at 13 months post-LT, whereas the remaining
2 with recurrence remained stable on systemic therapy
after resection of metastasis at the time of publication.
Tumor size was not related to recurrence, and the median cumulative diameter among transplanted patients
was 14.2 cm, and no patient had a cumulative tumor
diameter of <5 cm. Genetic mutation analysis was
performed and published for all patients. Results of 3
additional transplanted patients, for a total of 9, were
presented in abstract form in 2019.
An earlier experience using neoadjuvant therapy
followed by LT for iCCA was reported by Hong et al.
in 2011.[41] In this report, 38 patients underwent LT, including 25 with iCCA, with the remaining patients having pCCA. However, only 9 of 25 patients with iCCA
received any neoadjuvant therapy, whereas 9 had no
therapy and 7 had adjuvant therapy only. Of the 25 patients with iCCA who underwent LT, mean tumor size
was 6.5 cm, and 16 of 25 (61%) had multifocal disease.
Specific outcomes from this analysis are not reported
separately for iCCA versus pCCA, though the overall
5-year survival was 33% for patients undergoing LT
for CCA. Improved outcomes were noted in those with
pCCA compared to iCCA. The heterogeneity of the patients, including both iCCA and pCCA, as well as those
who did and did not receive neoadjuvant or adjuvant
therapy, pose a significant limitation to interpreting the
data.
The same group from UCLA recently published an
updated experience of 53 patients, including 31 with
iCCA.[42] In this new analysis, they separated the cohorts into those recently transplanted (n = 7; 2008–
2019) compared to those transplanted previously
(n = 22; 1985–
2007). In the most recent era, they
treated ~70% of patients with neoadjuvant therapy,
whereas in the previous era, only 22% received neoadjuvant therapy. In the most recent era, patients with
iCCA <6 cm received stereotactic beam radiotherapy
whereas those with tumors >6 cm or multifocal tumors
were treated with neoadjuvant chemotherapy consisting of a 5-fluorouracil-, capecitabine-, or gemcitabine-
based regimen in combination with oxaliplatin,
leucovorin, and cisplatin. The researchers note a trend
toward improved survival in the most recent era, though
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iCCA. The protocol is based on receiving neoadjuvant
therapy, achieving stable disease (determined based
on a minimum of 6-month radiographic response or
stability), followed LT.[22] To be eligible, patients needed
to have tumors confined to the liver with a solitary tumor
>2 cm or have multifocal disease without vascular or
O NGO I NG PROSPECTI V E TR I A LS
lymph node involvement. The group has published outFO R LT FO R i CCA
comes for 6 patients and reported on a total of 9 in
abstract form.[22]
There are currently three ongoing trials (Table 3) that
Nonetheless, there are several challenges with
aim to evaluate the role of LT for ICCA in patients not
these ongoing trials. The rarity of these tumors makes
amenable to LR: one for early iCCA, one for primary
recruitment difficult, particularly when only a few sites
or recurrent iCCA, and one for locally advanced disare participating in the study. Moreover, eligible paease requiring downstaging therapy. Of note, though
tients must not only fulfill size and number criteria, but
not registered as a clinical trial, the largest experience
also have an absence of any extrahepatic disease, in
to date with LT for locally advanced iCCA is a prospecsome cases have a living donor available, and also
tive case series based on an LT protocol established by
not be candidates for LR. As evidenced by the sevthe Methodist-MD Anderson Joint Cholangiocarcinoma
eral studies evaluating the outcomes of LT for iCCA,
Collaborative Committee (MMAJCCC).[22]
a consensus is lacking regarding whether iCCA and
NCT02878473 (Liver Transplantation for Early
mixed HCC-CCA should be considered jointly or sepIntrahepatic Cholangiocarcinoma) is based in the University
arately. The argument for considering them jointly is
Health Network in Toronto, Canada and the Hospital Clinic
that a reliable pre-LT assessment of these two entiof Barcelona, Spain. The enrollment goal is 30 patients,
ties is not always possible, either with imaging or a
and 2 have been enrolled. The primary outcome is 5-year
percutaneous biopsy.[74,75] This difficulty in diagnosis
patient survival. The inclusion criteria include liver cirrhois highlighted well in the studies shown in Table 2,
sis and a biopsy-proven iCCA ≤2 cm not amenable to LR.
where the iCCA was predominantly diagnosed inciAdditional criteria include a CA 19-9 ≤100 ng/mL.
dentally (Table 2). However, the argument against
NCT04556214 (Liver Transplantation for Non- considering the two entities jointly would be that
Resectable Intrahepatic Cholangiocarcinoma: a
combining the two may yield survival and recurrence
Prospective Exploratory Trial [TESLA]) is based in Oslo
estimates that are overly favorable, particularly if the
University (Oslo, Norway). It is a single group, open- dominant tumor phenotype is HCC. The difficulty in
label study design with a planned enrollment of 15 parthese patients is also the potential of several lesions
ticipants. The primary outcome is overall survival from
being unrecognized before LT. As a result, several lescreening. To meet the inclusion criteria, patients must
sions may be present in the explant, including iCCA,
be ineligible for LR based on tumor location or underlymixed HCC-CCA, and HCC can be present in any
ing liver dysfunction, have no extrahepatic disease, and
given liver.[76] Deducing which lesion is the driver
have good performance status. First-
time iCCA and
of adverse oncological outcomes and recurrence in
liver-only recurrent iCCA after previous LR is allowed.
this setting may be challenging or even impossible.
NCT04195503 (Liver Transplant for Stable,
Limiting heterogeneity in the study cohorts is critical
Advanced Intrahepatic Cholangiocarcinoma) is based
to ensure that treatment guidelines based on them
at the University Health Network in Toronto. It aims to
are as generalizable as possible. Donor scarcity is
evaluate the outcomes of LT for locally advanced, unreanother challenge, and though a patient meets other
sectable, nonmetastatic iCCA treated with neoadjuvant
inclusion criteria, they may not have a living donor
systemic therapy. Five-year patient survival is the priavailable or be able to receive a deceased donor
mary outcome measure, and the enrollment goal is 10
transplant in a timely manner if their physiological
patients. Since the study start date on December 10,
MELD score is low.
2019, 1 patient has been transplanted and 1 is awaiting
Several considerations will be relevant for ongoing
transplant workup. To be eligible for inclusion in the trial,
and future trials that seek to clarify the role of LT for
iCCA. Interdisciplinary collaborations and advances
patients must have a histologically confirmed iCCA, not
in radiology will be imperative to allow an accurate
be candidates for LR, and have a living donor available.
diagnosis that can be used to base future treatment
decisions on. This may require nontraditional methodologies such as machine learning and radiomics,
M M A JCCC PROSPECTI V E
a field of imaging-
based research to extract data
CASE SER I ES
from imaging as an imaging-based biomarker, to improve discrimination between lesions such as iCCA,
In this series, Lunsford et al. reported their experience
HCC, and mixed HCC-
CCA.[77,78] Next- generation
of an LT protocol for unresectable locally advanced
this was not significant. However, there were 4 patients
with iCCA who received both neoadjuvant chemotherapy and liver-directed therapy in the most recent era
who had a statistically significant survival advantage.

Liver transplantation for
Early Intrahepatic
cholangiocarcinoma

Liver Transplantation
for Non-Resectable
Intrahepatic
Cholangiocarcinoma: a
Prospective Exploratory
Trial (TESLA)

Liver Transplant for Stable,
Advanced Intrahepatic
Cholangiocarcinoma

Very early iCCA

Primary or
recurrent
iCCA after
LR

Locally
advanced
iCCA

NCT04195503

NCT04556214

NCT02878473

NCT No.

• Locally advanced, unresectable,
nonmetastatic iCCA that is
histologically confirmed
• Treated with neoadjuvant
systemic therapy
• Demonstration of disease
stability/regression for a
minimum of 6 months
• Have a living donor available

• Ineligible for LR based on tumor
location or underlying liver
dysfunction
• No extrahepatic disease
• Good performance status

• Biopsy-proven iCCA ≤2 cm
• Liver cirrhosis not amenable to
LR
• CA 19-9 ≤100 ng/mL

Inclusion Criteria

Abbreviations: DFS, disease-free survival; NCT, the National Clinical Trial number.

Study Title

Ongoing clinical trials evaluating LT in iCCA registered on www.clinicaltrials.gov

Population

TA B L E 3

• University Health Network
• Toronto, Canada

• Oslo University
• Oslo, Norway

• University Health Network
• Toronto, Canada
• Hospital Clinic of
Barcelona
• Barcelona, Spain

Lead Center(s)

Five-year patient
survival

OS from screening
and until 36
months after
inclusion

Five-year patient
survival

Primary Outcome

• Five-year DFS
• One-year patient survival

• OS from relapse
• DFS
• Start of new treatment/
change of strategy
• Time to decrease in physical
function and global health
score
• LT complication
• Development of other
malignancies
• Survival in relation to
biological markers

• Five-year disease recurrence
after LT

Secondary Outcomes
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FIGURE 1
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Proposed treatment approach to patients with iCCA and the role of LT (images created with BioRender.com)

sequencing methods can improve risk stratification
when selecting patients for trials and treatment and
potentially offer more targeted neoadjuvant therapy
options.[79–81] Both the static and dynamic role of biomarkers such as CA 19-9 should be evaluated, which
has been demonstrated to be associated with mortality in iCCA similar in magnitude to nodal metastases
and positive resection margins.[82]
The expanded use of marginal grafts, which have
shown significantly improved outcomes over time,[83]
and the use of normothermic machine perfusion to
salvage grafts that would otherwise have been discarded, may alleviate some of the prevailing scarcity,
though, in most countries, organ allocation policy does
not yet grant additional priority for iCCA. The recently
established National Liver Review Board in the USA
includes a guidance document intended to ensure
consistency in submitting and reviewing nonstandard
MELD exception requests. The guidance document is
subjected to ongoing review and revision by the OPTN
Liver Intestine Committee, including a period of public comment and submission to the OPTN Governing
Board for any recommended changes. Currently,
there is no guidance for LT in the setting of iCCA.
However, as further evidence accumulates either in
support of LT in iCCA or for settings where LT should
not be considered for iCCA, revision of the NLRB
guidance document to include such guidance may
be needed.[49] The use of living donor liver transplant
(LDLT) is another option that would secure a graft for
the patients enrolled in the trials, though not all patients have a suitable living donor, and not all centers
offer LDLT. Certain countries such as Norway, with a

less pronounced organ scarcity, may be instrumental in further accelerating trial results and exploring
the limits of patient selection, as has been observed
with the previous SECA trials with LT for patients with
colorectal liver metastases.[84] The TESLA trial is a
good illustration of these opportunities, given that it
allows the inclusion of patients with histologically verified iCCA regardless of size, either first-time iCCA or
with liver-only recurrence after previous LR.[85] The
role of bridging therapy in these patients remains to
be clarified and could potentially prolong the time
these patients can spend on the waitlist and possibly
improve outcomes. An evaluation of intention-to-treat
survival will also be necessary to gauge the proportion of patients listed for LT but who drop out for
tumor progression. Within this context, survival benefit may represent an endpoint, which can help clarify
the difference in survival with LT compared with other
modalities. Finally, given the rarity of the disease, national and international collaborative efforts between
institutions are vital to ensure that providers are aware
of the trials and can refer their patients to be screened
for possible inclusion.

SUM M A RY: R E A DY FO R PR I M E
TI M E?
LT has emerged as a potential treatment option with curative potential for a highly select group of patients with
iCCA. These include patients with very early disease
(≤2 cm) who are not eligible for LR because of significant liver dysfunction and those with locally advanced
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tumors without cirrhosis who can tolerate neoadjuvant
chemotherapy. If disease stability can be demonstrated
for at least 6 months, indicative of favorable biology, LT
can be considered under investigational protocols, as
highlighted in Figure 1.
The tumor biology of iCCA is typically more aggressive than HCC. Though a comparative evaluation
of waitlist outcomes between the two is naturally unable to be performed at this time, patients with pCCA,
a well-established LT indication, have been noted to
have a higher cumulative incidence of dropout at 6 and
12 months (pCCA 6-month, 13.2% vs. HCC 7.3% and
pCCA 12-month, 23.9% vs. HCC 12.7%) based on a
USA population-
based analysis of listing outcomes
from the UNOS registry.[86] It is possible that these
inferences can be extended to iCCA patients as well.
Consequently, strategies for how to mitigate potential
adverse waitlist outcomes while simultaneously improving posttransplant outcomes for potential future
patients listed for LT with iCCA will therefore have to
be carefully considered. Options to improve outcomes
of patients that are potential LT candidates may include
improved patient selection based on biology using enhanced staging techniques, including cell-
free DNA
and effective neoadjuvant therapies.[87] Tumor biology
will be a critical determinant of patient outcomes before
and after LT. Within this context, certain histological
growth patterns, like the tubular growth pattern of iCCA,
have a higher association with metastatic disease than
the papillary type.[88] In addition, specific genetic determinants, such as tumor protein p53, KRAS, and cyclin-
dependent kinase inhibitor 2A, may portend a worse
prognosis in unresectable iCCA patients and may be
helpful in further stratifying patients and aiding in refining treatment selection. At this time, however, there is a
lack of studies available on tumor growth patterns and
doubling times, which represents a significant impediment to a better understanding of this disease in the
setting of transplant listing.
There are recently published consensus statements from the International Liver Transplantation
Society Working Group on Transplant Oncology regarding the role of LT in iCCA.[89] These include a
moderate-
strength conditional recommendation regarding upfront LT in patients with very early iCCA (≤2
cm) and consideration for LT candidacy in patients
without cirrhosis in the presence of locally advanced
disease with disease stability after neoadjuvant therapy.[89] Moreover, based on moderately strong evidence, a strong recommendation was put forth to
pursue a biopsy in patients with cirrhosis being considered for LT with a liver nodule that has atypical
radiological features for HCC on cross-sectional imaging.[89] Genomic profiling through whole-genome
sequencing was conditionally recommended based
on low-level evidence to aid in identifying new molecular pathways and risk stratification.[89] Last, the
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treatment choice for iCCA should be LR, with the
highest level of evidence and a strong recommendation, and that LT should be reserved for patients
with unresectable disease only in the setting of strict
clinical trial protocols (moderate evidence, strong
recommendation).[89]
Historically, a 5-year survival exceeding 50% has
been considered acceptable when considering an indication for LT.[90] This outcome can likely be achieved
in a select group of patients with very early disease.[43]
Though several studies evaluating LT for iCCA have
failed to reproduce these results, the study cohorts have
been highly heterogeneous regarding both histological
and tumor morphometric groupings. Consequently, the
only ways to demonstrate that outcomes are acceptable
are robust prospective trials with strict selection criteria
to limit such heterogeneity. Within this context, LT for
iCCA should not be viewed in a vacuum. Instead, the
option of LT in this select group of patients should be
considered in light of the outcomes of alternative treatments such as various LRTs and systemic therapies,
which have generally shown inferior outcomes, though,
importantly, these therapies continue to evolve. Direct
comparative analyses between LT and such therapies
are currently unavailable. Radiological and genomic
advancements will aid in increasing diagnostic precision, improving risk stratification, and refining patient
selection. Given the rarity of iCCA and the strict selection criteria, dissemination of ongoing prospective trials
is imperative to maximize patients’ access to them and
accelerate the accrual process. In light of all these considerations, though LT for iCCA is not currently ready
for prime time, significant progress has been made in
the field. As a result, these efforts have helped pave a
promising path forward in improving future outcomes
for patients afflicted with this disease.
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